Objectif This proposal intends to set-up a coordination of public funded malaria vaccine development by establshing a collaborative strategy in malaria vaccine development sisting in formulation of shared strategic plans, and in development of common tools, optimised resources and iterative activities. This project will stimulate the community of problem-solvers by sharing information, by establishing a correct balance between collaboration and competition, by identifying and prioritising the most critical scientific, technical and regulatory questions. This will stitute a pool of resources who could be rapidly directed to obtain answers to these questions. This project will be the basis for the implementation of common standards for assessing research results and to maximise the sharing and the use of data, resources and know-how.The strategy for malaria vaccine development is based on two pillars: pharmaceutical development and clinical development. The overall objective of the proposal is to prepare for the creation of the enabling environment in the field of malaria vaccine development by solidating the Network of complementary expertise and resources. This SSA will focus on : 1.)Developing and implementing a rationale screening for malaria vaccine antigens, addressing the scientific, technical, regulatory and ethical straints. This implies to develop reliable assays for in-vitro and animal pre-clinical studies 2.)Design of clinical development strategy for malaria vaccine candidates developed in Europe - Definition of the go/no go criteria for entering in phase Ia clinical studies - Defining safety evaluation criteria - Defining immunological evaluation criteria. This implies to develop the methodology for standardisation of safety and immunological criteria, addressing the scientific, technical, regulatory and ethical straints. Champ scientifique medical and health scienceshealth sciencesinfectious diseasesmalariamedical and health scienceshealth sciencesparasitologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Thème(s) LSH-2004-3-4 - Realising ERA objectives LSH-2004-2.3.0-3 - Malaria vaccine development Appel à propositions FP6-2004-LIFESCIHEALTH-5 Voir d’autres projets de cet appel Régime de financement SSA - Specific Support Action Coordinateur STATENS SERUM INSTITUT Contribution de l’UE Aucune donnée Adresse Artillerivej 5 COPENHAGEN S Danemark Voir sur la carte Liens Site web Opens in new window Coût total Aucune donnée